PAUL CHAPLIN,PAUL HOWLEY,CHRISTINE MEISINGER-HENSCHEL
申请号：
US13588217
公开号：
US20120328650A1
申请日:
2012.08.17
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
